| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44033195 | HTLV-1 | ENSG00000180772.8 | protein_coding | AGTR2 | No | No | 186 | P50052 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | AGTR2 |
|---|---|
| DrugBank ID | DB16266 |
| Drug Name | Olodanrigan |
| Target ID | BE0003426 |
| UniProt ID | P50052 |
| Regulation Type | antagonist |
| PubMed IDs | 28255254; 24507377; 25315162 |
| Citations | Keppel Hesselink JM, Schatman ME: EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain. J Pain Res. 2017 Feb 20;10:439-443. doi: 10.2147/JPR.S128520. eCollection 2017.@@Rice ASC, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N, Raff M: EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383(9929):1637-1647. doi: 10.1016/S0140-6736(13)62337-5. Epub 2014 Feb 5.@@Smith MT, Muralidharan A: Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opin Ther Targets. 2015 Jan;19(1):25-35. doi: 10.1517/14728222.2014.957673. Epub 2014 Oct 15. |
| Groups | Investigational |
| Direct Classification | |
| SMILES | COC1=CC=C2CN([C@@H](CC2=C1OCC1=CC=CC=C1)C(O)=O)C(=O)C(C1=CC=CC=C1)C1=CC=CC=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL34124 |
